From Phosphocreatine to Performance: The Brain-Energy Hypothesis
Creatine monohydrate’s proposed cognitive effect begins with an energy-transfer system, not with the promise that a supplement makes the mind generally sharper. The useful question in this chapter is how creatine could plausibly support energy-demanding work in brain cells, and where that biological explanation stops short of proving better performance. Tracing that sequence gives us a way to read the human evidence without mistaking a mechanism for an outcome.
The energy-buffer pathway
Creatine is a nitrogen-containing organic acid made in the body and also obtained through food. After cells take it up, the compound participates in a linked system involving creatine, phosphocreatine, creatine kinase, and adenosine triphosphate, usually abbreviated ATP. ATP is the immediate energy currency used by cells. The 2024 review describes phosphocreatine as part of the process that helps regenerate ATP: creatine kinase catalyzes the breakdown of phosphocreatine, allowing energy transfer to be replenished when demand rises.
That sequence is easier to understand as a reserve-and-replenish system than as a stimulant. Creatine is not described in the supplied evidence as directly forcing a neuron to fire faster or as switching on a particular memory. Instead, the phosphocreatine system is a way of making energy transfer available when a cell needs to maintain demanding work. A cell that repeatedly spends ATP needs a way to restore it. Phosphocreatine participates in that restoration through the creatine-kinase reaction.
The word “buffer” describes timing as much as quantity. A cell does not need to wait for a completely new source of energy every time demand changes; it can draw on a linked chemical reserve while energy transfer is being maintained. That makes the proposed mechanism especially relevant to questions about sustained or rapid neural work. It does not mean that the brain is running out of fuel during an ordinary task, or that adding creatine will automatically improve any process that uses energy. It identifies a possible constraint and a possible way to test whether that constraint matters.
This distinction keeps the mechanism from becoming a metaphor for unlimited mental capacity. Neural performance depends on coordinated signaling, the properties of the task, and the condition of the person performing it. Energy availability is one part of that system. A reserve can support a process only if that process is actually limited by the relevant energy-transfer step. If another part of the task is the bottleneck, changing the reserve may produce no measurable difference even though the biochemical pathway is functioning normally.
The proposed brain mechanism also has to be interpreted at the right level. The review discusses cellular energy in the brain, but the measured outcomes are behavior: recall, accuracy, completion time, or a composite score. There is no direct line from a molecule’s participation in ATP regeneration to a conclusion about a person’s memories. The line has intermediate steps, and each step can add uncertainty. This is why a mechanism can make a trial worth running without telling us in advance what the trial will show.
The brain is relevant because neural tissue is metabolically active. Maintaining electrical gradients, transmitting signals, processing information, and coordinating networks all require energy. The review therefore presents brain energy metabolism as a plausible reason to investigate creatine beyond its athletic uses. If a task places a high demand on rapid processing or sustained coordination, researchers can reasonably ask whether the energy-buffer system changes the conditions under which performance is possible.
That “reasonably ask” is important. The pathway makes a prediction worth testing; it does not specify the size, direction, or reliability of a cognitive effect. Several links must connect the mechanism to a measured result. Creatine must participate in the relevant cells, the task must draw on a process that the intervention can influence, the test must be sensitive to that influence, and the study must be able to distinguish it from learning, fatigue, expectation, or ordinary variation between participants.
The proposed sequence can be represented this way:
The last step is not an afterthought. A biological pathway can be active without producing a detectable change on a particular test, and a test score can change without the change being large or consistent enough to matter in daily life. The mechanism therefore has two jobs in an evidence discussion. It explains why the intervention is plausible, and it identifies the kinds of conditions under which an effect might be easier to observe. It cannot, by itself, establish that the effect appears in adults taking a particular amount for a particular period.
The pathway also does not imply that more creatine must always produce more cognitive performance. The supplied evidence does not establish a dose-response rule for brain outcomes, a threshold at which energy becomes limiting, or a point at which additional supplementation stops mattering. Those questions belong to human intervention research. The mechanism supplies a map of possible relationships; it does not fill in the values on that map.
From energy supply to a testable cognitive endpoint
To turn the mechanism into a human study, researchers need to decide what “performance” means. Memory, attention, processing speed, and executive function are not four labels for the same ability. They involve overlapping mental operations, but the tests used to represent them can demand different combinations of encoding, recall, inhibition, flexibility, accuracy, and speed.
Memory is a useful example because it can be tested in several ways. A participant might need to recall words, numbers, locations, or images after a delay. These tasks all involve memory, but they do not place the same demands on encoding and retrieval. A pooled memory result can therefore summarize a family of measurements rather than one uniform behavior. That makes the endpoint scientifically meaningful, but it also makes the details of the synthesis important: which tests were grouped, how their effects were represented, and whether several tests came from the same participants.
Attention creates a related distinction between a score and a time. A score may reflect how many responses were correct or how accurately a participant maintained focus. A time outcome asks how long the task took. A supplement could, in principle, affect speed without improving accuracy, or improve accuracy without making a response faster. The 2024 review reported a positive result for attention time but not for attention scores. Those findings are not interchangeable, and the difference is exactly why the mechanism must be connected to a specific endpoint rather than to the broad word “attention.”
Processing speed works in the same way. Completing a task faster may be relevant to rapid information handling, but it does not automatically mean that a person understands complex material better or makes better decisions. A time-based result can also be sensitive to task design, practice, motor response, or the balance between speed and accuracy. The review reported a benefit for processing-speed time while finding no significant effect for processing-speed scores. That pattern invites a focused question about which component changed, not a broad conclusion that the brain became more capable in every respect.
Executive function illustrates a further limit. Planning, inhibition, switching, and cognitive flexibility are often grouped together because they all concern the control of thought and action. Yet a test that measures one of those operations is not a complete measure of executive control. The 2024 synthesis did not find a significant overall improvement in executive-function scores or executive-function time. That null result does not disprove the energy hypothesis, but it does show that biological plausibility has not translated uniformly across cognitive domains.
The review discusses additional possible routes by which creatine could affect cognition. It mentions neurotransmitter function, synaptic efficacy and plasticity, neuromodulation, and protection against oxidative stress. These ideas extend the energy model: creatine might matter not only because cells need ATP, but also because signaling and cellular resilience could influence how neural networks perform. In the supplied evidence, however, these are proposed explanations. They are not isolated causal pathways demonstrated by the adult trials in the review.
Each proposed route suggests a different kind of test, which is another reason not to treat “cognition” as a single endpoint. An energy-transfer explanation might predict a clearer pattern in tasks that demand rapid or sustained processing. A signaling explanation might be relevant to learning or memory, but it would still need to be connected to a defined memory measure. A neuroprotective explanation might matter most under conditions involving disease or cellular stress, yet the available review contains limited evidence in specific clinical populations. An oxidative-stress hypothesis may be biologically interesting while remaining too distant from the measured test to explain a particular result on its own.
These routes can coexist, but they should not be merged casually. If a review reports a memory effect, it does not follow that the effect was caused by synaptic plasticity rather than energy availability. If a study finds no change in executive function, that does not show that none of the proposed pathways operate. The human result is an observation at the end of several possible chains, and the supplied evidence does not isolate which chain, if any, carries the effect.
That distinction can be expressed as a chain of different claim types. “Creatine participates in phosphocreatine-based energy transfer” is a biological description. “Creatine may help under some energy-demanding neural conditions” is a mechanistic hypothesis. “Participants receiving creatine performed differently on a defined memory or speed task than controls” is a human outcome claim. “Creatine improves learning, work performance, or quality of life” is a broader functional claim. Each step requires evidence beyond the previous one.
A human trial tests the chain by placing the intervention next to a comparison and measuring a defined outcome, not by asking participants to confirm the mechanism. If the creatine group performs differently from the control group, that difference is evidence about the task under those study conditions. It is not a direct reading of phosphocreatine inside each participant’s brain, and it does not identify which biological route produced the result. The randomized comparison helps with causal attribution at the intervention level; it does not turn an endpoint-specific result into a general account of cognition.
This distinction also explains why a composite label can hide important information. Combining several tests may make a summary easier to read, but it can conceal whether the signal came from recall, speed, accuracy, or another component. A mechanism-first interpretation therefore asks two questions in order: what process could plausibly be affected, and what exact behavior was actually measured? The second question is the one that anchors the claim to human evidence.
The chain can also fail at different points. A study may use a task that is too noisy to detect a modest effect. Participants may differ in baseline diet, health, or cognitive reserve. A short intervention may not reveal the same pattern as a longer one, while a longer intervention may introduce other sources of variation. A pooled analysis may combine outcomes that are not sufficiently comparable. None of these possibilities tells us in advance whether creatine works; they explain why a plausible mechanism needs careful measurement and analysis.
For the same reason, the mechanism cannot answer questions that the supplied trials did not directly study. It cannot establish a treatment for a neurological disease, prove prevention of cognitive decline, or determine a best dose for an individual. It cannot show that a faster laboratory response will improve everyday judgment. Those claims may be important, but they sit farther along the evidence chain and require outcomes designed to address them.
The next task is therefore empirical rather than speculative: inspect how the 2024 review selected adult trials, combined their measurements, and separated positive endpoints from null ones. Only then can we judge how closely the reported results match the brain-energy hypothesis—and how much uncertainty enters when many different tests are brought together.